跳至主要内容
临床试验/2024-516967-10-00
2024-516967-10-00招募中4 期

The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis

Medical University Of Vienna1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2024年12月10日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
招募中
入组人数
250
试验地点
1
主要终点
Changes in sex steroid levels

研究概览

简要总结

Do cholesterol-lowering drugs reduce the levels of steroid hormones?

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Inclusion criteria for all cohorts except the new-onset low-dose statin therapy patient group: - Age 18–75 years - LDL cholesterol levels >116 mg/dl - Previously prescribed dyslipidemia treatment according to the ESC/EAS guidelines with either atorvastatin >=40 mg, rosuvastatin >=20 mg or PCSK-9 inhibitors such as Praluent, Repatha or Inclisiran Inclusion criteria for the new-onset low-dose statin therapy patient group: - No history of statin treatment - Age 18–75 years - LDL cholesterol levels >116 mg/dl before statin treatment - Previously prescribed dyslipidemia treatment according to the ESC/EAS guidelines with simvastatin <=20 mg, atorvastatin <=10 mg or rosuvastatin <=10 mg

排除标准

  • Severe liver disease - Pregnancy - Malignant disorders - Hepatitis B and Hepatitis C - HIV - Primary psychiatric disorder other than depression (ICD-10: F32 and F33) - Exclusion criteria for the MR investigations: claustrophobia, implants in the human body that do not fit to the guidelines on the feasibility of MR measurements.

结局指标

主要结局

Changes in sex steroid levels

Changes in sex steroid levels

次要结局

未报告次要终点

研究者

申办方类型
Educational Institution
责任方
Principal Investigator
主要研究者

Division of Endocrinology and Metabolism, Department of Medicine III

Scientific

Medical University Of Vienna

研究点 (1)

Loading locations...

相似试验